SequelSEC

BridgeBio Oncology Therapeutics, Inc. BBOT

Pharmaceutical Preparations · CIK 0001869105 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$145.82M
Fiscal year ended 2025-12-31
Free cash flow
-$114.50M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$465.15MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-08-13
Float per share$5.81Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity1.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-08-13, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio12.34x85th

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported net income of -$134.04M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from BridgeBio Oncology Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BridgeBio Oncology Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$145.82M-$80.86M-$41.69K
Net income-$134.04M-$74.28M-$41.69K
Research & development$121.20M$73.11MUnavailable
Weighted-average diluted sharesshares 31.14MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$0$0Unavailable
Diluted EPS$-4.30$-5,756.41Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$24.62M$7.76M$41.69K
Selling & marketingUnavailableUnavailableUnavailable

Balance

BridgeBio Oncology Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$373.69M$30.85MUnavailable
Total assets$448.38M$164.30M$332.89K
Current assets$432.40M$158.69MUnavailable
Total liabilities$37.28M$19.58M$396.46K
Current liabilities$35.04M$19.58M$396.46K
Total equity incl. NCI$411.10M-$178.64M-$115.64M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.37M$3.07MUnavailable

Cash flow

BridgeBio Oncology Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$113.89M-$55.03MUnavailable
Capital expenditures$606.00K$49.00KUnavailable
Investing cash flow$73.33M-$120.53MUnavailable
Financing cash flow$383.40M$206.29MUnavailable
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$5.87M$4.42MUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

BridgeBio Oncology Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$114.50M-$55.08MUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio12.34x8.10xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BBOT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-12-31

Difference 323358000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 115577431 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.